title: Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review.
abstract: Apatinib is a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. Previous studies have suggested that apatinib is safe and effective in some solid tumors. We report one case with advanced hepatocellular carcinoma (HCC), who received apatinib combined with transhepatic arterial chemotherapy and embolization (TACE), and chemotherapy respectively. TACE was administered three times once a month, using lipiodol 10ml, oxaliplatin 150mg, and tegafur 1g. The dose of apatinib was 500 mg/d from day 4 to 24. After TACE, the patient received chemotherapy of regimen FOLFOX4, oxaliplatin intravenously at 85 mg/m2 on day 1, calcium levofolinate 200 mg/m2 on day 1 and 2, 5-fluorouracil 400 mg/m2 intravenously and 5-fluorouracil 600 mg/m2 intravenously pumped for 22h on day 1 and 2, cycled every two weeks for seven cycles. He took concurrently apatinib with a dose of 500mg daily from 1 to 10 days per cycle. He was confirmed as partial response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST). The level of serum alpha-fetoprotein (AFP) decreased from 60500 ng/ml to 12.7 ng/ml, and the progression free survival (PFS) time was more than eight months. It indicated that apatinib may be a superior choice for HCC patients.
authors.affiliation: Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.|Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.
authors.forename: Peisi
authors.initials: P
authors.lastname: Kou
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Intervention, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.
authors.forename: Wenbo
authors.initials: W
authors.lastname: Shao
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Zhu
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.
authors.forename: Jingze
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.
authors.forename: Haiyong
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.
authors.forename: Li
authors.initials: L
authors.lastname: Kong
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|School of Medicine and Life Sciences, University of Jinan - Shandong Academy of Medical Sciences, Jinan, China.|Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
authors.forename: Jinming
authors.initials: J
authors.lastname: Yu
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D016461:Chemoembolization, Therapeutic; D018572:Disease-Free Survival; D004998:Ethiodized Oil / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011725:Pyridines / Q000627:therapeutic use*; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D011725:Pyridines; D000077150:Oxaliplatin; D005641:Tegafur; C553458:apatinib; D004998:Ethiodized Oil; D002955:Leucovorin; D005472:Fluorouracil
keywords: apatinib; hepatocellular carcinoma; targeted therapy